搜尋
CorMedix Inc
CRMD添加自選
8.750USD
+0.280+3.31%
收盤 07/02, 13:00（美東）報價延遲15分鐘
686.45M總市值
3.60本益比TTM
關鍵數據
8.550今開
8.840最高
1.04M成交量
3.60本益比TTM
49.75本益比動
--股利TTM
1.33%換手率
8.470昨收
8.420最低
6.80M成交額
虧損本益比靜
1.57市淨率
0.00%股息率 TTM
37.51%ROA
17.43052週最高
0.84量比
-17.93M淨利潤
78.40M總股本
2.4327每股盈餘TTM
1.46Beta
65.59%ROE
6.12552週最低
4.96%振幅
82.50%毛利率
686.45M總市值
0.94回報/風險
3.10%風險率
TradingKey CorMedix Inc股票評分
單位: USD 更新時間: 2026-07-02操作建議
CorMedix Inc當前公司基本面數據相對非常健康，增長潛力很大。當前估值合理，在藥品行業排名50/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為15.20。中期看，股價處於上升通道。近一個月，市場表現一般，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
CorMedix Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
CorMedix Inc亮點
亮點風險
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
業績轉盈
公司業績轉盈，最新年度盈利美元
估值高估
公司最新PE估值3.60，處於3年歷史高位
機構減倉
最新機構持股43.28M股，環比減少30.09%
查克·羅伊斯持倉
明星投資者查克·羅伊斯持倉，最新持倉1.52M股
分析師目標
基於
5
分析師
買入
評級
15.200
目標均價
+98.95%
漲幅空間
CorMedix Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
CorMedix Inc簡介
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
公司代碼CRMD
公司CorMedix Inc
CEOTodisco (Joseph)
網址https://cormedix.com/
相關品種
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%熱門品種
52990.700
+148.200 (+0.28%)
29601.800
+290.400 (+0.99%)
7509.800
+38.300 (+0.51%)
14984.000
+181.000 (+1.22%)
69724.000
+1576.000 (+2.31%)
6385.400
+32.600 (+0.51%)
68.863
+0.519 (+0.76%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4173.020
+51.110 (+1.24%)
常見問題
CorMedix Inc(CRMD)的當前股價是多少？
CorMedix Inc(CRMD)的當前股價是 8.75。
CorMedix Inc 的股票代碼是什麼？
CorMedix Inc的股票代碼是CRMD。
CorMedix Inc股票的52週最高點是多少？
CorMedix Inc股票的52週最高點是17.43。
CorMedix Inc股票的52週最低點是多少？
CorMedix Inc股票的52週最低點是6.12。
CorMedix Inc的市值是多少？
CorMedix Inc的市值是685.96M。
現在CorMedix Inc(CRMD)的股票是買入、持有還是賣出？
根據分析師評級，CorMedix Inc(CRMD)的總體評級為買入，目標價格為15.20。
CorMedix Inc(CRMD)股票的每股收益（EPS TTM）是多少
CorMedix Inc(CRMD)股票的每股收益（EPS TTM）是2.26。